These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24819296)

  • 41. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.
    Diskin B; Adam S; Cassini MF; Sanchez G; Liria M; Aykut B; Buttar C; Li E; Sundberg B; Salas RD; Chen R; Wang J; Kim M; Farooq MS; Nguy S; Fedele C; Tang KH; Chen T; Wang W; Hundeyin M; Rossi JAK; Kurz E; Haq MIU; Karlen J; Kruger E; Sekendiz Z; Wu D; Shadaloey SAA; Baptiste G; Werba G; Selvaraj S; Loomis C; Wong KK; Leinwand J; Miller G
    Nat Immunol; 2020 Apr; 21(4):442-454. PubMed ID: 32152508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen.
    Hayden MS; Grosmaire LS; Norris NA; Gilliland LK; Winberg G; Tritschler D; Tsu TT; Linsley PS; Mittler RS; Senter PD; Fell HP; Ledbetter JA
    Tissue Antigens; 1996 Oct; 48(4 Pt 1):242-54. PubMed ID: 8946677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
    Maurer MF; Lewis KE; Kuijper JL; Ardourel D; Gudgeon CJ; Chandrasekaran S; Mudri SL; Kleist KN; Navas C; Wolfson MF; Rixon MW; Swanson R; Dillon SR; Levin SD; Kimbung YR; Akutsu M; Logan DT; Walse B; Swiderek KM; Peng SL
    Nat Commun; 2022 Apr; 13(1):1790. PubMed ID: 35379805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting T cell costimulation in autoimmune disease.
    Stuart RW; Racke MK
    Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T helper-independent activation of human CD8+ cells: the role of CD28 costimulation.
    Van Gool SW; Zhang Y; Kasran A; de Boer M; Ceuppens JL
    Scand J Immunol; 1996 Jul; 44(1):21-9. PubMed ID: 8693288
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.
    Wei S; Shreiner AB; Takeshita N; Chen L; Zou W; Chang AE
    Cancer Res; 2008 Jul; 68(13):5432-8. PubMed ID: 18593946
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High macrophage PD-L1 expression not responsible for T cell suppression.
    Goldman N; Lomakova YD; Londregan J; Bucknum A; DePierri K; Somerville J; Riggs JE
    Cell Immunol; 2018 Feb; 324():50-58. PubMed ID: 29305065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
    J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Absence of B7-dependent responses in CD28-deficient mice.
    Green JM; Noel PJ; Sperling AI; Walunas TL; Gray GS; Bluestone JA; Thompson CB
    Immunity; 1994 Sep; 1(6):501-8. PubMed ID: 7534617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile.
    Broeren CP; Gray GS; Carreno BM; June CH
    J Immunol; 2000 Dec; 165(12):6908-14. PubMed ID: 11120816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
    Butte MJ; Keir ME; Phamduy TB; Sharpe AH; Freeman GJ
    Immunity; 2007 Jul; 27(1):111-22. PubMed ID: 17629517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD4 T-cell help programs a change in CD8 T-cell function enabling effective long-term control of murine gammaherpesvirus 68: role of PD-1-PD-L1 interactions.
    Dias P; Giannoni F; Lee LN; Han D; Yoon S; Yagita H; Azuma M; Sarawar SR
    J Virol; 2010 Aug; 84(16):8241-9. PubMed ID: 20534854
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
    Yamazaki T; Akiba H; Koyanagi A; Azuma M; Yagita H; Okumura K
    J Immunol; 2005 Aug; 175(3):1586-92. PubMed ID: 16034097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of programmed death 1 ligands by murine T cells and APC.
    Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
    J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.
    Haspot F; Fehr T; Gibbons C; Zhao G; Hogan T; Honjo T; Freeman GJ; Sykes M
    Blood; 2008 Sep; 112(5):2149-55. PubMed ID: 18577709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
    Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
    J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cowpox virus encodes a protein that binds B7.1 and B7.2 and subverts T cell costimulation.
    Wang X; Piersma SJ; Elliott JI; Errico JM; Gainey MD; Yang L; Nelson CA; Yokoyama WM; Fremont DH
    Proc Natl Acad Sci U S A; 2019 Oct; 116(42):21113-21119. PubMed ID: 31575740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Immunomodulatory Gallotanin-Rich Fraction From
    Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
    Front Immunol; 2020; 11():584959. PubMed ID: 33312174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
    Juneja VR; McGuire KA; Manguso RT; LaFleur MW; Collins N; Haining WN; Freeman GJ; Sharpe AH
    J Exp Med; 2017 Apr; 214(4):895-904. PubMed ID: 28302645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.